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A 29-year-old man had been treated for hypertension for 10 years. He suffered from speech
disturbance caused by cerebral infarction, and further examinations were performed. Computerized
tomography scan and magnetic resonance imaging revealed a left adrenal tumor 6 cm in size. The
radioisotope (MIBG) accumulated in the left adrenal gland. The serum noradrenalin levels were high.
Thus, the diagnosis of pheochomocytoma in left adrenal tumor was made. He noticed ejaculation
disturbance 5 days after starting administration of doxazosin at the dose of 3 mg/day for pre-operative blood
pressure control. Sperm was observed in the urine sampling obtained after masturbation, thus his
ejaculation disturbance was considered to be retrograde ejaculation. Laparoscopic left adrenalectomy was
performed. After the operation, his blood pressure normalized and the administration of doxazosin has not
been necessary. He could perform ejaculation without any trouble after stopping doxazosin intake. The
bladder neck conditions measured by ultrasonography were the same before and after the administration of
doxazosin. The present case is a very rare case of ejaculation disturbance caused by non-selective alpha 1
blocker doxazosin.
(Hinyokika Kiyo 55 : 377-380, 2009)
























(CT) を施行したところ，6 cm 大の左副腎腫瘍が認
められ (Fig. 1a）， 3月 3日に当科紹介となった．
現症・検査成績 : 身長 178 cm，体重 69 kg．画像診
断では，magnetic resonance imaging (MRI) にて T2 高
信号 (Fig. 1b），核医学的検査 (MIBG) にて左副腎腫
瘍部に集積を認めた．検査所見では，血中ノルアドレ




を 0.5 mg/day から開始し，漸増して最終的には 20
mg/day まで増量した．
ドキサゾシンを 3.0 mg/day 内服中の 3月19日にマ
スターベーションを試みたところ，射精感やオルガズ
ムはあるものの，精液の射出がないことに気づいた．






































Fig. 1. a : Computerized tomography (CT) finding.
Left adrenal tumor of 6 cm in size was
observed in plain CT (arrow). b : Magnetic
resonance imaging (MRI) finding. T2






Fig. 2. a : Transrectal ultrasonography findings of
the bladder neck during doxizosin adminis-
tration. The patient suffered from ejacu-
lation disturbance. His bladder neck ap-
peared slightly opened (arrow). b : Trans-
abdominal ultrasonography findings of the
bladder neck after stop doxizosin adminis-
tration. The patient could ejaculate with
no trouble. The bladder neck conditions
(arrow) were almost the same as before
treatment.
























































を Table 1 に示す1,3~6,8,13~16)．















Table 1. Summary of α blockers and ejaculatory disorder
国内の主な商品名 射精障害発生率（報告文献番号)
非選択的 α 遮断薬
アルフゾシン (alfuzosin) 日本未発売 0％（1），0.4％（13)
テラゾシン (terazosin) バソメット 0.3％（1)
プラゾシン (prazosin) ミニプレス 0％（14)
ウラピジル (urapidil) エブランチル 2.8％(15)
ドキサゾシン (doxazosin) カルデナリン 2例（使用上の注意改訂)＋本症例
選択的 α 遮断薬
タムスロシン (tamsulosin) ハルナール 4.5％（1），7.3％（4），10.0％（16），30.0％（5)
ナフトピジル (naftopidil) フリバス 3.0％（3)
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